|Year : 2020 | Volume
| Issue : 3 | Page : 191-199
Localization and restaging of carcinoma prostate by 68Gallium prostate-specific membrane antigen positron emission tomography computed tomography in patients with biochemical recurrence
Nikhil Seniaray1, Ritu Verma1, Sudhir Khanna2, Ethel Belho1, Ankur Pruthi1, Harsh Mahajan1
1 Department of Nuclear Medicine and PET/CT, Mahajan Imaging Centre, Sir Ganga Ram Hospital, New Delhi, India
2 Department of Urology, Sir Ganga Ram Hospital, New Delhi, India
|Date of Submission||10-Oct-2019|
|Date of Acceptance||21-Apr-2020|
|Date of Web Publication||1-Jul-2020|
Dr. Nikhil Seniaray
Department of Nuclear Medicine and PET/CT, Mahajan Imaging Centre, Sir Ganga Ram Hospital, New Delhi
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Introduction: Radical prostatectomy (RP) and radical radiotherapy (RT) are well established primary curative options for localized prostate cancer. Despite technical improvements, prostate-specific antigen (PSA)-recurrence after RP and RT is a common clinical scenario. We aimed to assess the role of 68Gallium (68Ga) prostate-specific membrane antigen positron emission tomography computed tomography (PSMA PET/CT) in patients with biochemical recurrence of prostate cancer after RP or RT for the detection and localization recurrent and metastatic disease.
Materials and Methods: We ambispectively (70 retrospective and 100 prospective) analyzed the data of men with biochemical recurrence post-RP and post-RT who were evaluated by 68Ga PSMA PET/CT at our institute. We aimed to assess the relationship between serum PSA levels and the probability of having a positive scan in patients with recurrent prostate cancer.
Results: The study included 170 men, all had adenocarcinoma of the prostate, 124/170 had previous RP and 46/170 had prior RT. The median serum PSA in the RP group was 1.8 ng/ml and 5.2 ng/ml in the RT group. In the post-RP cohort, the detection rate of 68Ga PSMA PET/CT was 39.3% for PSA 0.2 to <0.5 ng/ml, 47.3% for PSA 0.5 to <1 ng/ml, 68.4% for PSA 1 to <2 ng/ml and 93.1% for PSA ≥2 ng/ml. In the post-RT group, the detection rate was 88.8% for PSA 2 to <4 ng/ml and 100% for PSA ≥4 ng/ml.
Conclusions: 68Ga PSMA PET/CT provides a novel imaging modality for the detection of prostate cancer recurrence and metastases at low posttreatment PSA levels, which may help in directing appropriate salvage treatments.
|How to cite this article:|
Seniaray N, Verma R, Khanna S, Belho E, Pruthi A, Mahajan H. Localization and restaging of carcinoma prostate by 68Gallium prostate-specific membrane antigen positron emission tomography computed tomography in patients with biochemical recurrence. Indian J Urol 2020;36:191-9
|How to cite this URL:|
Seniaray N, Verma R, Khanna S, Belho E, Pruthi A, Mahajan H. Localization and restaging of carcinoma prostate by 68Gallium prostate-specific membrane antigen positron emission tomography computed tomography in patients with biochemical recurrence. Indian J Urol [serial online] 2020 [cited 2020 Sep 25];36:191-9. Available from: http://www.indianjurol.com/text.asp?2020/36/3/191/288631
| Introduction|| |
Prostate cancer is the most common solid cancer in men. Its incidence increases with age and thus is a major health concern for the aging population of the world. Following definitive treatment of prostate cancer by radical prostatectomy (RP) or radiotherapy, cancer recurrence is heralded by an increase in the serum prostate-specific antigen (PSA) levels which is called the biochemical recurrence., Depending on the patient population studied, 15%–40% of the patients experience a rise in serum PSA levels.,, The European Association of Urology guidelines defines the biochemical recurrence after RP as an increase in the serum PSA value above 0.2 ng/ml and over a threshold of 2 ng/ml above the nadir value post radiation therapy.,
Determining whether the recurrence is local (within the prostate or at the urethral/bladder anastomosis), regional (pelvic) or distant (outside the pelvis) is critical when considering appropriate further treatment options.
The reported sensitivity of the currently available imaging methods such as the transrectal ultrasound, computed tomography (CT), and magnetic resonance imaging range between 25% and 54% for the detection of local recurrence and 30%–80% for the detection of lymph nodal metastasis.,,, Although functional imaging with 18 Fluorine-fluorodeoxyglucose or 11 Carbon-choline (11 C-choline) positron emission tomography (PET)/CT has better efficacy than the other imaging techniques, their sensitivity depends on the serum PSA levels and currently there are no reliable imaging methods to localize the disease in patients with biochemical recurrence.,,,
Prostate-specific membrane antigen (PSMA) represents a cell surface target suitable for imaging as it is expressed by nearly all the prostate cancer cells with enhanced expression levels in the poorly differentiated, metastatic, and hormone-refractory carcinomas.,, PSMA is labeled with 68 Gallium (68 Ga), a generator produced positron emitting short lived radionuclide which makes them suitable for PET imaging. It can detect prostate cancer relapses and metastases with high diagnostic sensitivity.,,, The present study aims to assess the role of 68 Ga PSMA PET CT in patients with biochemical recurrence after RP or radiotherapy, for the detection and localization of recurrent and metastatic disease and to identify the relationship between the detection rate of 68 Ga PSMA PET CT and post treatment serum PSA levels.
| Materials and Methods|| |
Ambispective evaluation of 170 patients (70 retrospective and 100 prospective) with biochemical recurrence after treatment of prostate cancer was performed between May 2014 and January 2018. All these individuals underwent 68 Ga PSMA PET/CT scan based on the predefined inclusion criteria of serum PSA level >0.2 ng/ml and >2 ng/ml above the nadir, post RP and post radiotherapy, respectively. The patients who did not receive definitive treatment for carcinoma prostate and those, in whom the serum PSA level did not fall below 0.2 ng/ml after RP, were excluded from the study. Demographic data of each patient was recorded, including relevant clinical examination findings, histopathology, Gleason's score, serum PSA levels, and treatment history.
For the labeling of 68 Ga PSMA,68 GaCl3 in 0.6 M hydrochloric acid was obtained from 68 Ge/68 Ga generator (iThemba, South Africa). PSMA HBED-CC (40 μg in 0.4 ml) was added to GaCl3 with 700 mg HEPES buffer (pH 5–6.5) in 0.5 ml distilled water. The mixture was allowed to react at 100°C for 20 min in water bath and then cooled to room temperature for 30 min. After cooling, the solution was passed through C-18 purification cartridge to remove the unlabeled GaCl3 and the radio labeled compound was eluted with 5 ml ethanol. All the patients were given intravenous injection of 132–222 MBq (4–6 mCi) of 68 Ga-PSMA and underwent PET/CT scanning from the vertex to the mid-thigh using a dedicated PET/CT scanner within 45 ± 15 min after injection. Between five and eight bed positions were used, with an acquisition time of 5 min for each position. PET images were reconstructed using the ordered set expectation maximization algorithm, CT attenuation correction, dead time correction, and decay correction. A delayed sequence of pelvis was acquired after furosemide injection. Images were interpreted at the advantage window workstation equipped with fusion software. All scans were evaluated independently and blindly by two experienced Nuclear Medicine physicians. PET images were scanned for areas of increased radiotracer uptake and any site of focal PSMA uptake higher than the background, at sites other than the physiological sites of PSMA uptake, were considered as a lesion.68 Ga-PSMA uptake was expressed as the maximal standardized uptake value corrected for the administered dose and patient body weight.
Statistical analysis was performed with the Statistical Package for the Social Science System (SPSS) version 17.0(Chicago: SPSS Inc.). Continuous variables were presented as mean ± standard deviation or median (interquartile range) for non-normally distributed data. Categorical variables were expressed as frequencies and percentages. Unpaired Student t-test was used to compare the mean values of different groups. Nominal categorical data between the groups were compared using the Chi-square test. For all the statistical tests, P < 0.05 was considered as statistically significant.
The study was approved by the ethics committee (EC/07/17/1203, Sir Ganga Ram Hospital, New Delhi), and an informed written consent was taken from all the patients. We confirm the availability of, and access to, all original data reported in this study.
| Results|| |
The study included a total of 170 patients [Table 1] of adenocarcinoma prostate of which 124 had undergone prior RP with or without adjuvant radiotherapy or androgen deprivation therapy and 46 had received prior radiotherapy (either external beam radiation therapy [EBRT] or brachytherapy).
Post radical prostatectomy group
Out of the 124 patients who met the inclusion criteria, 62 patients did not receive any treatment after RP, 9 received adjuvant radiotherapy, 42 received hormonal therapy, and 11 had received both adjuvant radiotherapy and hormonal therapy. The mean time for serum PSA recurrence was 49.77 ± 44.44 months (range 2–184 months) and median serum PSA level was 1.8 ng/ml.
Eighty-seven of the 124 patients (70.1%) showed 1 or more areas of 68 Ga PSMA positivity, suggestive of recurrence [Figure 1] and [Table 2]. The detection rates improved with the rising serum PSA levels (Chi-square statistic 32.074, P < 0.001). The mean serum PSA in patients with a positive scan was significantly higher than that in patients with a negative scan (t-statistic-2.452, P = 0.015).
|Figure 1: A 61-year-old male, known case of adenocarcinoma prostate (Gleason's score 8), post radical prostatectomy with pelvic lymphadenectomy and raised serum prostate-specific antigen ~3.8 ng/ml. 68Gallium-prostate-specific membrane antigen positron emission tomography computed tomography images show prostate-specific membrane antigen avid ill-defined lesion in the prostatic bed region (a-e) and prostate-specific membrane antigen avid abdomino-pelvic lymph nodes (a and f-i)|
Click here to view
|Table 2: Detection rates of 68Ga prostate-specific membrane antigen positron emission tomography/computed tomography by serum prostate-specific antigen levels after radical prostatectomy and radiotherapy|
Click here to view
Our data also reveal an improved rate of detection for patients with higher (postsurgery) Gleason's score. The detection rate was 63.3% (38/60) for Gleason score ≤7 which increased to 76.5% (49/64) for Gleason score ≥8. This relationship between high Gleason score and detection rate was found to be statistically significant (Chi-square statistic 8.36, P value ~ 0.03).
Lymph nodal metastases was detected in 65.5% (57/87) of the patients and was found to be the most common site of metastases followed by the bone, local recurrence (prostatic bed region) and visceral metastases [Table 3]. The pelvic lymph nodal group was the most common site of metastases at all the serum PSA values [Table 4]. Visceral metastases were seen in 6 of the patients and were most commonly detected in the lungs.
|Table 3: Regions/combination of regions detected by 68Ga prostate-specific membrane antigen positron emission tomography/computed tomography in the postradical prostatectomy and post-radiotherapy groups|
Click here to view
|Table 4: Positive lymph nodal/combination of lymph nodal groups detected by 68Ga prostate-specific membrane antigen positron emission tomography/computed tomography in the postradical prostatectomy and postradiotherapy groups|
Click here to view
Forty-six patients who met the predefined inclusion criteria were included in this study. Thirty-nine patients received additional hormonal therapy after radiotherapy. The mean time to serum PSA recurrence was 49.15 ± 24.32 months (range 12–111 months) and the median serum PSA level was 5.2 ng/ml.
Forty-four of the 46 patients (95.6%) showed 68 Ga PSMA positivity, suggestive of recurrent disease [Figure 2], [Figure 3] and [Table 2]. The probability of detecting recurrence post radiotherapy increased from 88.8% (16/18) for the patients with serum PSA between 2 to <4 ng/ml to 100% for patients with serum PSA ≥4 ng/ml. At serum PSA levels >2 ng/ml local recurrence was the most common site of PSMA avid recurrent disease followed by lymph node, bone and visceral metastases [Table 3]. Lymph nodal metastases were the second most common site of metastases and were present in 63.6% (28/44) patients with pelvic lymph nodes being the most common site [Table 4].
|Figure 2: A 74-year-old male, known case of adenocarcinoma prostate (Gleason's score 6), post radiotherapy with rising serum prostate-specific antigen (9.5 ng/ml from 0.72 ng/ml). 68Gallium-prostate-specific membrane antigen positron emission tomography computed tomography images, show prostate-specific membrane antigen avid ill-defined lesion in the prostate gland (b and c) and prostate-specific membrane antigen avid lymph nodes in the right iliac region (a, d and e)|
Click here to view
|Figure 3: A 62-year-old male, known case of carcinoma prostate (Gleason's score 6), post radiotherapy with raised serum prostate-specific antigen ~2.78 ng/ml. 68Gallium-prostate-specific membrane antigen positron emission tomography computed tomography revealed prostate-specific membrane antigen avid ill-defined lesion in the prostate gland (b and c) and prostate-specific membrane antigen avid sclerotic lesion in the left 5th rib (a, d and e)|
Click here to view
Improved recurrence detection rates were observed with increasing (Pre-radiotherapy) Gleason's score. The detection rate was 91.6% (22/24) for Gleason's score ≤7 and 100% (22/22) for Gleason's score ≥8; however, the results were not statistically significant.
Follow-up studies [Figure 4] and [Figure 5] were available for 68 patients (54 post RP and 14 post radiotherapy). All these patients received hormonal treatment, 8 patients received additional chemotherapy and 8 patients had received radiotherapy for bone metastases. Following the treatment, one patient had complete response, 34 patients had partial response, 24 patients had stable disease, and 9 patients had progressive disease.
|Figure 4: A 67-year-old male, known case of adenocarcinoma prostate (Gleason's score 6), post radical prostatectomy with raised serum prostate-specific antigen ~5.2 ng/ml, diagnosed with prostate-specific membrane antigen avid lung nodules in the initial baseline study, on hormonal treatment since 1 year, follow-up 68Gallium-prostate-specific membrane antigen positron emission tomography computed tomography was done for rising serum prostate-specific antigen (13.2 ng/ml from 5.2 ng/ml). Comparative 68Gallium-prostate-specific membrane antigen positron emission tomography computed tomography study, showed increase in size, number, and prostate-specific membrane antigen avidity in the right lung nodules in the follow-up study (b, e, f, i and j) on comparison with the baseline study (a, c, d, g and h)|
Click here to view
|Figure 5: A 73-year-old male, known case of adenocarcinoma prostate (Gleason's score 7) status; post robotic radical prostatectomy with raised serum prostate-specific antigen 1.04 ng/ml. Diagnosed with bone metastasis to L2 vertebra in the initial baseline 68Gallium-prostate-specific membrane antigen positron emission tomography computed tomography, post stereotactic radiotherapy to L2 vertebra and on hormonal treatment. Follow-up 68Gallium-prostate-specific membrane antigen positron emission tomography computed tomography was done to assess the treatment response which showed increase in the extent of sclerosis with reduction in prostate-specific membrane antigen avidity of the lesion in the follow up 68Gallium-prostate-specific membrane antigen positron emission tomography computed tomography (b, e and f) on comparison with the baseline (a, c and d)|
Click here to view
| Discussion|| |
PSA relapse after RP and radiotherapy is a common clinical scenario. Biochemical recurrence is defined by the rise of serum PSA value above 0.2 ng/ml and 2 ng/ml more than nadir value after RP and radiotherapy, respectively, and occurs long before the recurrent disease can be localized clinically or by imaging. The goal in these patients is to distinguish prostatic bed recurrence from metastatic disease, as this affects further treatment. The localization of site of recurrence, in patients with biochemical recurrence, especially at low PSA values, is a major challenge for all the available imaging modalities.,,
In this study, we evaluated 68 Ga PSMA PET/CT for the localization and detection of recurrent disease in patients with biochemical recurrence. Our study cohort included 124 patients post RP and 46 patients post radiotherapy with biochemical recurrence. Overall, we observed a 70.1% detection rate in the post RP group. The detection rate improved with rising serum PSA levels with a highest detection rate of 93.1% which was achieved at serum PSA level more than 2 ng/ml. These findings are consistent with the meta-analysis performed by Perera et al. which showed a 68 Ga PSMA PET/CT positivity rate for serum PSA levels 0.2–0.99, 1.00–1.99, and >2.0 at 58%, 76%, and 95%, respectively. Another important finding of our study is the 42.5% detection rate at serum PSA values <1 ng/ml, which is higher as compared to that reported with choline based PET tracers which have a detection rate of 19% at PSA levels below 1 ng/ml.,, Comparative analysis of various studies reportred in the literature with the present study is shown in [Table 5].
|Table 5: Comparative analysis of various studies in the literature with the present study|
Click here to view
Our data shows a statistically significant higher detection rate in patients with a Gleason's score ≥8 versus ≤7, which could be potentially attributed to the fact that immunohistochemically, PSMA expression is usually higher in the lesions with a higher Gleason's score as compared to the lesions with a lower Gleason's score. Similar findings have been reported by Eiber et al. and Kabasakal et al.
68 Ga PSMA PET/CT scan has shown to improve the chances of detection of the site of recurrence, particularly at low serum PSA levels. In our study, we found that 39.2% (11/28) of the patients with serum PSA values between 0.2 to <0.5 ng/ml had metastatic disease, out of which, in 36.3% the site of recurrence was bone and in 54.5% it was the lymph nodes [Table 3]. Differentiating between local and distant recurrence in patients with BCR and PSA levels <0.5ng/ml has particular clinical impact, as these patient are ideal candidates for salvage pelvic radiotherapy according to the European Urology Association Guidelines  which defines the PSA level of 0.5ng/ml as the upper limit for salvage radiotherapy. Hence, identifying the site of recurrence can change their clinical management. Also, we found that distant metastasis can be present at low PSA levels and salvage pelvic radiotherapy may not be an appropriate treatment option in these patients.
In the post-RP group, lymph nodal metastases were the most common site of recurrence at all the serum PSA levels, [Table 3] with pelvic lymph nodes [Table 4] being the most commonly involved (89.2%). These patients may be amenable to salvage treatment with either lymph node dissection or targeted radiotherapy. Thus, early 68 Ga-PSMA PET/CT may be beneficial in identifying the patients who may benefit from salvage treatment.
Local recurrence (prostatic bed region) after RP was detected in about 28.73% (25/87) of the patients. This low rate of local recurrence can be attributed to complete surgical resection in most of the patients and also that many patients received adjuvant radiotherapy. Hence, most of the patients were expected to have site of recurrence outside the prostate bed.
Supra-diaphragmatic lymph nodes and visceral metastases were present in approximately 15.7% (9/57) and 6.9% (6/87) of the patients with serum PSA >1 ng/ml, respectively. The lungs were the most common site of visceral metastases and were involved in 5/6 patients. These uncommon sites can easily be detected with 68 Ga PSMA PET/CT owing to the high lesion to background ratio, better contrast, and whole-body imaging. Early detection of metastatic disease may also result in earlier referral for chemotherapy, which has recently been shown to improve survival in hormone naive metastatic prostate cancer.
We report an overall detection rate of 95.6% (44/46) in the post-radiotherapy group comprising of the patients who had been managed by EBRT or brachytherapy. Local recurrence (within the prostate gland) was identified in 79.5% (35/44) of the patients, followed by lymph node and bone metastases in 63.6% (28/44) and 59.09% (26/44), respectively. Of the lymph nodal groups, pelvic lymph nodes were the most commonly involved (92.7%). We, in our study, have adhered to the definition of biochemical recurrence after post radiotherapy and thus included only those patient who had serum PSA >2 ng/ml above the nadir value, however, Meredith et al. showed that 68 Ga-PSMA PET CT can detect lesions in patients with serum PSA <2 ng/ml and suggested that if salvage treatment is being considered 68 Ga-PSMA PET CT should be performed before the serum PSA rises >2 ng/ml.
Compared to the reported detection rates between 34% and 88% for 11 C-choline, 43%–79% for 18 F-choline, and 59%–80% for 11 C-acetate,,,68 Ga-PSMA PET CT offers a substantially higher detection efficacy. As known from other PET tracers, the detection rate of 68 Ga-PSMA ligand PET CT also increases in proportion with the rising PSA values. We found an overall detection rate of 77.05% (131/170) and a detection rate of 97.02% (98/108) in patients with serum PSA ≥2 ng/ml.
Follow-up studies were performed for 68 patients (54 post RP and 14 post radiotherapy) to assess the treatment response. Persistence of similar findings, increase/decrease in the number, size and the PSMA avidity of the lesions following treatment indirectly validated the findings detected on the first 68 Ga PSMA PET/CT. In our study, 1 out of the 68 patients had complete response, 34 patients had partial response, 24 patients had stable disease, and remaining 9 patients had progressive disease following treatment.
One of the limitations of our study is its retrospective-prospective nature. Furthermore, the histopathological analysis of the lesions detected on 68 Ga-PSMA PET/CT was not performed, and could have resulted from false positive lesions. Although, the follow-up studies indirectly confirmed the findings of prior 68 Ga-PSMA PET/CT and reduced the false positive rates, they were available for only 68 patients. Another potential limitation is that the number of patients evaluated is quite small especially those with low PSA levels.
| Conclusions|| |
68 Ga-PSMA PET/CT imaging has a very high efficiency of >95% at serum PSA level ≥2 ng/ml for the detection of prostate cancer recurrence and metastasis. This modality currently surpasses all the other available imaging modalities for the restaging of prostate cancer. The findings of 68 Ga-PSMA PET/CT can affect treatment decisions; however, the overall impact of changing management decisions based on 68 Ga-PSMA PET/CT findings is still unknown and requires further research.
Financial support and sponsorship: Nil.
Conflicts of interest: There are no conflicts of interest.
| References|| |
Seigel RL, Miller KD, Jemal J. Cancer statistics 2016. CA Cancer J Clin 2016;66:7-30.
Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al
. EAU Guidelines on Prostate Cancer Part1: Screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 2014;65:124-37.
Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-7.
Van Poppel H, Vekemans K, Da Pozzo L, Bono A, Kliment J, Montironi R, et al
. Radical prostatectomy for locally advanced prostate cancer: Results of a feasibility study (EORTC 30001). Eur J Cancer 2006;42:1062-7.
Zumste ZS, Spratt DE, Romesser PB, Pei X, Zhang Z, Polkinghorn W, et al
. The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy. Eur Urol 2015;67:1009-16.
Heidenreich A, Bastian BJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al
. EAU Guidelines on Prostate Cancer. Part II: Treatment of advanced, relapsing and castration resistant prostate cancer. Eur Urol 2014;65:467-79.
Bott SR. Management of recurrent disease after radical prostatectomy. Prostate Cancer Prostatic Dis 2004;7:211-6.
Beer AJ, Eiber M, Souvatzoglou M, Schwaiger M, Krause BJ. Radionuclide and hybrid imaging of recurrent prostate cancer. Lancet Oncol 2011;12:181-91.
Oyen RH, Van Poppel HP, Ameye FE, Van de Voorde WA, Baert AL, Baert LV. Lymph node staging of localized prostatic carcinoma with CT and CT-guided fine-needle aspiration biopsy: Prospective study of 285 patients. Radiology 1994;190:315-22.
Rouvière O, Vitry T, Lyonnet D. Imaging of prostate cancer local recurrences: Why and how? Eur Radiol 2010;20:1254-66.
Mari Aparici C, Seo Y. Functional imaging for prostate cancer: Therapeutic implications. Semin Nucl Med 2012;42:328-42.
Krause BJ, Souvatzoglou M, Tuncel M, Herrmann K, Buck AK, Praus C, et al
. The detection rate of [11C] choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2008;35:18-23.
Yoshida S, Nakagomi K, Goto S, Futatsubashi M, Torizuka T. 11C-choline positron emission tomography in prostate cancer: Primary staging and recurrent site staging. Urol Int 2005;74:214-20.
Heinisch M, Dirisamer A, Loidl W, Stoiber F, Gruy B, Haim S, et al
. Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: Meaningful at PSA & 5 ng/ml? Mol Imaging Biol 2006;8:43-8.
Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997;3:81-5.
Murphy GP, Elgamal AA, Su SL, Bostwick DG, Holmes EH. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer 1998;83:2259-69.
Eder M, Schafer M, Bauder-Würst U, Haberkorn U, Eisenhut M, Kopka K. Preclinical evaluation of a bi-specific low-molecular heterodimer targeting both PSMA and GRPR for improved imaging and therapy of prostate cancer. Prostate 2014;74:659-68.
Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschick BA, et al
. PET imaging with a (68Ga) gallium-labelled PSMA ligand for the diagnosis of prostate cancer: Bio-distribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 2013;40:486-95.
Kabasakal L, Demirci E, Ocak M, Akyel R, Nematyazar J, Aygun A, et al
. Evaluation of PSMA PETCT imaging using 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging. Nucl Med Commun 2015;36:582-7.
Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al
. The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2015;42:197-209.
Eiber M, Maurer T, Soutvatzoglou M, Beer AJ, Ruffani A, Haller B, et al
. Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med 2015;56:668-74.
Harisinghani MG, Barentsz J, Hahn PF, Deserno WM. Non-invasive detection of clinically occult lymph-node metastases in prostate cancer. N
Engl J Med 2003;348:2491-9.
Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, et al
. Sensitivity, specificity, and predictors of positive 68
Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: A systematic review and meta-analysis. Eur Urol 2016;70:926-37.
Graute V, Jansen N, Ubleis C, Seitz M, Hartenbach M, Scherr MK, et al
. Relationship between PSA kinetics and [18F] fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy. Eur J Nucl Med Mol Imaging 2012;39:271-82.
Castellucci P, Fuccio C, Rubello D, Schiavina R, Santi I, Nanni C, et al
. Is there a role for 11C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase of 1.5 ng/mL. Eur J Nucl Med Mol Imaging 2011;38:55-63.
Kabasakal L, Demirci E, Nematyazar J, Akyel R, Razavi B, Ocak M, et al
. The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels. Nucl Med Commun 2017;38:149-55.
James ND, Sydes MR, Mason MD, Clarke NW, Dearnaley DP, Spears MR, et al
. Docetaxel and/or zoledronic acid for hormone-naive prostate cancer:First overall survival results from STAMPEDE (NCT00268476). J Clin Oncol 2015;33:5001.
Meredith G, Wong D, Yaxley J, Coughlin G, Thompson L, Kua B, et al
. The use of 68Ga-PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer. BJU Int 2016;118:49-55.
Giovacchini G, Picchio M, Briganti A, Cozzarini C, Scattoni V, Salonia A, et al
. [11C]choline positron emission tomography/computerized tomography to restage prostate cancer cases with biochemical failure after radical prostatectomy and no disease evidence on conventional imaging. J Urol 2010;184:938-43.
Cimitan M, Bortolus R, Morassut S, Canzonieri V, Garbeglio A, Baresic T, et al
. [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: Experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 2006;33:1387-98.
Oyama N, Miller TR, Dehdashti F, Siegel BA, Fischer KC, Michalski JM, et al
. 11C-acetate PET imaging of prostate cancer: Detection of recurrent disease at PSA relapse. J Nucl Med 2003;44:549-55.
Verburg FA, Pfister D, Heidenreich A, Vogg A, Drude NI, Vöö S, et al
. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score. Eur J Nucl Med Mol Imaging 2016;43:397-403.
[Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5]
[Table 1], [Table 2], [Table 3], [Table 4], [Table 5]